First case of PML in Tysabri-naive Gilenya patient
This article was originally published in Scrip
Executive Summary
A multiple sclerosis patient taking Novartis's Gilenya (fingolimod) has been reported to have developed the potentially fatal condition PML (progressive multifocal leukoencephalopathy). Although rare cases of PML have been reported with Gilenya before, this is the first time such a case has not been associated with prior use of rival treatment, Tysabri (natalizumab; Biogen Idec; scripintelligence.com, 16 April 2012).